Update in the management of extraintestinal manifestations of inflammatory bowel disease

Current Gastroenterology Reports

Volumn 15, Issue 3, 2013, Pages

  Patil, Seema A ^a   Cross, Raymond K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Ankylosing spondylitis; Aphthous stomatitis; Crohn's disease; Episcleritis; Erythema nodosum; Extraintestinal manifestations; Inflammatory bowel disease; Primary sclerosing cholangitis; Pyoderma gangrenosum; Sacroiliitis; Spondyloarthropathy; Ulcerative colitis; Uveitis

Indexed keywords

ARTICLE; ENTERITIS; GENETIC PREDISPOSITION; HUMAN; SCLERITIS; SCLEROSING CHOLANGITIS; UVEITIS;

CHOLANGITIS, SCLEROSING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; SCLERITIS; UVEITIS;

MLCS; MLOWN;

EID: 84879893023     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-013-0314-8     Document Type: Article

References (45)

1. Greenstein AJ, Janowitz HD, Sachar DB. The extra- intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401-12.
2. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-9.
3. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and HLA genes. Gastroenterology. 2002;123:714-8. (Pubitemid 34977077)
4. Field EA, Allan RB. Oral ulceration-etiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther. 2003;18:949-62. (Pubitemid 37475954)
5. Greer Jr RO, Lindenmuth JE, Juarez T, et al. A double-blind study of topically applied 5 % amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg. 1993;51:243-8.
6. Binnie WH, Curro FA, Khandwala A, et al. Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent. 1997;18:1116-8.
7. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281-93.
8. Weedon D. The vasculopathic reaction pattern. In: Weedon's skin pathology, 3rd ed. Elsevier Limited; 2010. p. 195.
9. Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatol Treat. 2001;12:13-7. (Pubitemid 32385592)
10. Le Cleach L, Moguelet P, Perrin P, et al. Is topical monotherapy effective for localized pyoderma gangrenosum? Arch Dermatol. 2011;147:101-3.
11. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273-83. (Pubitemid 40979585)
12. Brooklyn TN, Dunnill GS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial. Gut. 2006;55:505-9.
13. Cariñanos I, Barreiro-De Acosta M, Domènech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:E153-4.
14. Jabs DA, Mudun A, Dunn JP, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469-76.
15. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
16. Kahn P, Weiss M, Imundo LF, et al. Favorable response to highdose infliximab for refractory childhood uveitis. Ophthalmology. 2006.
17. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319-24. (Pubitemid 46586527)
18. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447-51. (Pubitemid 41117431)
19. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-12. (Pubitemid 41057986)
20. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916-26.
21. Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondyloarthropathy. Arthritis Rheum. 2001;44:2728-36.
22. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83:703-9.
23. Brakenhoff L, van der Heijde D, Hommes W. IBD and arthropathies: a practical approach to its diagnosis and management. Gut. 2011;60:1426-35.
24. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebocontrolled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-11. (Pubitemid 43199691)
25. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442-52.
26. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002;97:2688-90.
27. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27:2860-5.
28. Oostveen J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol. 1999;26:1953-8. (Pubitemid 30007064)
29. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346-52. (Pubitemid 30416320)
30. RevickiDA, LuoMP,Wordsworth P, et al.Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol. 2008;35:1346-53. (Pubitemid 352000782)
31. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population- based study. Am J Gastroenterol. 2001;96:1116-22. (Pubitemid 32319146)
32. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107-14. (Pubitemid 46072050)
33. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975-80. (Pubitemid 351451987)
34. Gluck M, Cantone NR, Brandabur JJ, et al. A 20-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032-9.
35. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308-12. (Pubitemid 32207314)
36. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1059-66. (Pubitemid 32319137)
37. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol. 2008;24:377-83. (Pubitemid 351535898)
38. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336:691-5. (Pubitemid 27102683)
39. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464-72. (Pubitemid 41597389)
40. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808-14.
41. Chapman R, Fevery J, Kalloo A, et al. Diangosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660-78.
42. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30:1121-7. (Pubitemid 29510847)
43. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48-54. (Pubitemid 41115048)
44. Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213:21-5.
45. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451-8.